TORONTO--(BUSINESS WIRE)--A hallmark of this year's ICAD meeting was the wealth of new clinical trials information in Alzheimer’s Disease (AD). Years of basic and preclinical research have paved the road for development of new medications and biologics. Results from many new clinical trials were provided, ranging from promising Phase I and II trials to some disappointing Phase II and III results.
